The first clinical study on melanoma was carried out by Baldi and colleagues [51], who reported significant HtrA1 upregulation in primary tumours compared with that in metastases, and suggested that HtrA1 expression could be an indicator of disease progression. The gene discussed is HTRA1; the disease is melanoma.